Drugs / CT0596
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06730256 | Jul 2025 → Jan 2027 expected | plasma cell leukemia, refractory plasma cell neoplasm | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 0 | NCT06988059 | Jun 2025 → Jan 2027 expected | plasma cell leukemia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 0 | NCT06718270 | Dec 2024 → Jan 2027 expected | plasma cell leukemia, refractory plasma cell neoplasm | Shanghai Changzheng Hospital | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2026-08-04 | CARsgen Therapeutics Co., Ltd. | Regulatory CARsgen’s CT0596 Received IND Clearance from the NMPA for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma carsgen.com ↗ |
| 2026-06-15 | CARsgen Therapeutics Co., Ltd. | Results CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026 carsgen.com ↗
As of May 10, 2026, with a median follow-up of 6.97 months, 6 patients maintained responses. |
| 2025-12-29 | CARsgen Therapeutics Co., Ltd. | Regulatory CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596 carsgen.com ↗
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that it has submitted two separate Investigational New Drug (IND) applications to the National Medical Products Administration (NMPA) for its allogeneic BCMA-targeted CAR-T cell therapy product, CT0596. |
| 2025-12-08 | CARsgen Therapeutics Co., Ltd. | Results CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting carsgen.com ↗
Six patients achieved a partial response (PR) or better: 3 achieved complete response/stringent complete response (CR/sCR) (all in the full-dose lymphodepletion group), 1 achieved very good partial response (VGPR), and 2 achieved PR. |
| 2025-11-04 | CARsgen Therapeutics Co., Ltd. | Results Abstract for CARsgen’s Allogeneic BCMA CAR-T Product CT0596 Available on ASH Website carsgen.com ↗
CT0596 demonstrated preliminary favorable tolerability and encouraging efficacy signals. |
| 2025-11-03 | CARsgen Therapeutics Co., Ltd. | Results CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B carsgen.com ↗
The data showed that both allogeneic CAR-T products demonstrated initially favorable safety profiles and encouraging efficacy signals. |
| 2025-10-19 | CARsgen Therapeutics Co., Ltd. | Results Case Report | Preliminary Clinical Data of CARsgen’s Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia carsgen.com ↗
As of the data cutoff date (Oct 17, 2025), two patients with relapsed/refractory pPCL had been enrolled. |
| 2025-05-12 | CARsgen Therapeutics Co., Ltd. | Results CARsgen Announces Preliminary Clinical Data for Allogeneic BCMA CAR-T CT0596, Demonstrating Favorable Safety and Efficacy carsgen.com ↗
Key findings from up to four months of follow-up include: No dose-limiting toxicities (DLTs), ≥Grade 3 cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or graft-versus-host disease (GVHD) were reported. |
All press releases naming this drug 11 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT0596 | “A Clinical Study to Explore the Safety, Efficacy, and Pharmacokinetics of CT0596 CAR-T Cell Injection in Patients With Relapsed/Refractory Multiple Myeloma and...” NCT06718270 ↗2“A Clinical Study to Explore the Safety, Efficacy, and Pharmacokinetics of CT0596 CAR-T Cell Injection in Patients With Relapsed/Refractory Multiple Myeloma and...” NCT06730256 ↗ “A Study of CT0596 in Plasma Cell Leukemia” NCT06988059 ↗ |
| Modality | Cell therapy | “CT0596 CAR-T Cell Injection” NCT06730256 ↗ |